Royalty Pharma reported revenue of $690.10M and net income of $266.64M for the quarter ended Sep 2026, up 13.3% year over year. This income statement covers 30 quarters of results from Jun 2019 through Sep 2026, standardized by Business Quant from the company’s SEC filings.
| Income StatementIncome Statement | Jun2019 | Sep2019 | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 | Sep2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue & Cost | ||||||||||||||||||||||||||||||
| Interest expenses | ||||||||||||||||||||||||||||||
| Interest ExpensesInterest Expense | 46.97M | 47.06M | 46.97M | 46.98M | 46.96M | 46.95M | 46.95M | 46.03M | 47.26M | 44.23M | 49.01M | 66.51M | 65.76M | 65.26M | 68.67M | 79.56M | 94.17M | 93.72M | 93.62M | 90.49M | ||||||||||
| Net interest income | ||||||||||||||||||||||||||||||
| Provision for Credit LossesProvisions | 266.51M | 184.62M | 105.71M | 305.06M | 308.85M | 118.80M | 241.23M | 277.14M | -76.51M | 583.60M | 212.43M | -227.60M | 164.04M | -127.14M | -203.94M | 12.14M | 23.11M | -197.49M | 268.22M | -88.32M | ||||||||||
| Non-interest income | ||||||||||||||||||||||||||||||
| Income - Equity | -38.02M | 0.40M | 0.74M | -3.25M | -6.86M | 34.61M | -0.77M | -5.22M | 0.27M | -14.15M | 1.70M | 10.41M | 31.65M | 6.44M | 2.69M | 15.95M | 4.01M | 21.76M | 4.08M | 9.23M | ||||||||||
| Non-Interest Income - Total | -38.02M | 0.40M | 0.74M | -3.25M | -6.86M | 34.61M | -0.77M | -5.22M | 0.27M | -14.15M | 1.70M | 10.41M | 31.65M | 6.44M | 2.69M | 15.95M | 4.01M | 21.76M | 4.08M | 9.23M | ||||||||||
| Revenue | 575.70M | 562.05M | 535.96M | 573.46M | 565.75M | 683.97M | 538.20M | 536.31M | 596.07M | 567.98M | 537.27M | 564.69M | 593.64M | 568.25M | 578.67M | 609.29M | 621.99M | 630.58M | 674.14M | 690.10M | ||||||||||
| Operating Items | ||||||||||||||||||||||||||||||
| Amortization - Intangibles | 5.80M | 5.67M | ||||||||||||||||||||||||||||
| Selling, General & AdministrativeSG&A | 46.16M | 51.54M | 51.84M | 50.69M | 73.23M | 85.70M | 47.63M | 57.23M | 59.19M | 57.65M | 54.71M | 56.72M | 67.59M | 110.71M | 179.77M | 118.73M | 164.27M | 159.49M | 161.89M | 150.10M | ||||||||||
| Other Non-Interest ExpenseOther Non-Int. Exp. | 370.33M | 285.12M | 106.32M | 330.56M | 975.18M | 119.30M | 241.73M | 327.64M | -76.01M | 584.10M | 212.93M | -227.10M | 164.54M | -76.64M | 189.10M | 63.40M | 69.34M | -91.95M | 379.14M | 129.17M | ||||||||||
| Operating ExpensesOpex | 422.28M | 342.33M | 158.16M | 381.25M | 1,048.40M | 205.00M | 289.36M | 384.87M | -16.83M | 641.75M | 267.64M | -170.38M | 232.13M | 34.07M | 368.87M | 182.14M | 233.61M | 67.54M | 541.02M | 279.27M | ||||||||||
| Non-operating items | ||||||||||||||||||||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 10.64M | 9.53M | 10.92M | 14.03M | 43.85M | 16.70M | 25.65M | 23.44M | 6.50M | 7.42M | 13.38M | 17.51M | 9.04M | 11.29M | 8.33M | 6.90M | 7.07M | 6.23M | 5.13M | 5.34M | ||||||||||
| Other Non Operating IncomeOther Non Op Inc. | -4.92M | -1.76M | 70.77M | 14.99M | -2.15M | 4.28M | 0.39M | -10.39M | -18.31M | -3.69M | 6.00M | 1.35M | -11.19M | -3.06M | -1.54M | 2.43M | -9.17M | -2.20M | -1.50M | -1.88M | ||||||||||
| Non Operating IncomeNon Op. Inc. | -99.75M | -91.64M | 113.81M | 28.20M | -127.38M | 30.12M | 102.50M | -29.37M | 104.69M | 69.50M | -75.25M | 71.28M | -27.16M | -99.75M | -117.16M | 17.06M | -32.47M | -94.78M | -51.63M | -144.20M | ||||||||||
| Net income details | ||||||||||||||||||||||||||||||
| EBT | 53.67M | 128.08M | 491.60M | 220.41M | -610.03M | 509.09M | 351.34M | 122.08M | 717.59M | -4.27M | 194.38M | 806.36M | 334.35M | 434.43M | 92.64M | 444.21M | 355.91M | 468.26M | 81.49M | 266.64M | ||||||||||
| Income After Tax | 53.67M | 128.08M | 491.60M | 220.41M | -610.03M | 509.09M | 351.34M | 122.08M | 717.59M | -4.27M | 194.38M | 806.36M | 334.35M | 434.43M | 92.64M | 444.21M | 355.91M | 468.26M | 81.49M | 266.64M | ||||||||||
| Income from Continuing OperationsIncome (Continuing) | 53.67M | 128.08M | 491.60M | 220.41M | -610.03M | 509.09M | 351.34M | 122.08M | 717.59M | -4.27M | 194.38M | 806.36M | 334.35M | 434.43M | 92.64M | 444.21M | 355.91M | 468.26M | 81.49M | 266.64M | ||||||||||
| Consolidated Net IncomeConsol Net Inc. | 53.67M | 128.08M | 491.60M | 220.41M | -610.03M | 509.09M | 351.34M | 122.08M | 717.59M | -4.27M | 194.38M | 806.36M | 334.35M | 434.43M | 92.64M | 444.21M | 355.91M | 468.26M | 81.49M | 266.64M | ||||||||||
| Net Income Attributable to Noncontrolling InterestsNCI Net Income | 45.77M | 76.32M | 187.09M | 77.76M | -153.95M | 168.33M | 123.71M | 49.96M | 223.25M | -9.05M | 92.37M | 262.37M | 126.14M | 195.08M | 60.46M | 155.99M | 141.71M | 173.57M | 63.60M | 121.96M | ||||||||||
| Income towards Parent CompanyParent Net Inc | 7.90M | 51.76M | 304.50M | 142.65M | -456.08M | 340.76M | 227.63M | 72.11M | 494.34M | 4.78M | 102.00M | 543.99M | 208.21M | 239.35M | 32.18M | 288.22M | 214.21M | 294.69M | 17.88M | 144.68M | ||||||||||
| Net Income towards Common StockholdersNet Income | 7.90M | 51.76M | 304.50M | 142.65M | -456.08M | 340.76M | 227.63M | 72.11M | 494.34M | 4.78M | 102.00M | 543.99M | 208.21M | 239.35M | 32.18M | 288.22M | 214.21M | 294.69M | 17.88M | 144.68M | ||||||||||
| Additional items | ||||||||||||||||||||||||||||||
| EPS (Basic) | 0.02 | 0.12 | 0.70 | 0.32 | -1.04 | 0.76 | 0.51 | 0.16 | 1.10 | 0.01 | 0.23 | 1.22 | 0.46 | 0.55 | 0.08 | 0.67 | 0.50 | 0.67 | 0.04 | 0.32 | ||||||||||
| EPS (Diluted) | 0.02 | 0.09 | 0.50 | 0.23 | -1.04 | 0.56 | 0.38 | 0.12 | 0.82 | 0.01 | 0.17 | 0.92 | 0.35 | 0.41 | 0.06 | 0.52 | 0.38 | 0.53 | 0.03 | 0.26 | ||||||||||
| Weighted Average Shares OutstandingWtd. Avg. Shares | 414.79M | 433.96M | 436.32M | 439.29M | 437.96M | 445.61M | 450.41M | 448.44M | 447.60M | 448.62M | 451.02M | 447.63M | 448.19M | 435.48M | 423.51M | 431.89M | 429.80M | 436.79M | 445.06M | 446.03M | ||||||||||
| Weighted Average Shares Outstanding (Diluted)Wtd. Avg. Shares (Dil.) | 414.80M | 607.20M | 607.21M | 607.23M | 437.97M | 607.25M | 605.86M | 601.14M | 602.90M | 597.48M | 596.91M | 592.73M | 594.11M | 578.10M | 562.30M | 559.61M | 564.46M | 556.84M | 556.90M | 557.00M | ||||||||||
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 607.18M | 607.18M | 607.22M | 607.22M | 607.22M | 607.23M | 601.82M | 598.39M | 597.44M | 597.44M | 594.39M | 589.18M | 589.11M | 566.46M | 583.17M | 579.02M | 577.11M | 576.19M | 575.00M | 574.16M | ||||||||||
| Operating IncomeOp. Inc | 153.42M | 219.72M | 377.79M | 192.21M | -482.66M | 478.97M | 248.84M | 151.44M | 612.90M | -73.77M | 269.63M | 735.07M | 361.51M | 534.18M | 209.80M | 427.16M | 388.38M | 563.04M | 133.12M | 410.84M |
Pull Royalty Pharma's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=RPRX&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "RPRX", "statement": "IS", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=RPRX&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();